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DOI 10.1016/j.ccr.2012.04.011SUMMARYDNA damage induced by ionizing radiation activates the ATM kinase, which subsequently stabilizes and acti-
vates the p53 tumor suppressor protein. Although phosphorylation of p53 by ATM was found previously to
modulate p53 levels and transcriptional activities in vivo, it does not appear to be a major regulator of p53
stability. We have utilized mice bearing altered Mdm2 alleles to demonstrate that ATM phosphorylation of
Mdm2 serine 394 is required for robust p53 stabilization and activation after DNA damage. In addition, we
demonstrate that dephosphorylation of Mdm2 Ser394 regulates attenuation of the p53-mediated response
to DNA damage. Therefore, the phosphorylation status of Mdm2 Ser394 governs p53 protein levels and func-
tions in cells undergoing DNA damage.INTRODUCTION
The p53 tumor suppressor has been called the ‘‘guardian of the
genome’’ due to its ability to prevent genotoxic insults from
inducing heritable alterations in damaged cells (Lane, 1992).
In response to cellular stresses such as DNA double-strand
breaks, hypoxia, and inappropriate oncogene activation, the
p53 transcription factor is stabilized within the cell and induces
the expression of various p53 target genes involved in cell
cycle arrest, apoptosis, and senescence (Vousden and Lu,
2002). These p53-dependent effector pathways regulate the
proliferation and propagation of damaged cells to limit cellular
transformation and tumorigenesis, and mice deleted for p53
rapidly develop thymic lymphomas, sarcomas and other tumor
types (Donehower et al., 1992). Additionally, over 50% of all
human tumors harbor p53 mutations (Soussi and Be´roud,
2001; Hollstein et al., 1991). These findings clearly demonstrate
the necessity of functional p53 signaling in suppressing
tumorigenesis.Significance
The p53-mediated DNA damage response pathway suppresses
insults. A better understanding of the mechanisms that govern
developing new cancer therapies, because tumors that harbor
activity, and because selectively regulating p53 functions migh
work determines that mouse Mdm2 Ser394 phosphorylation (h
p53 activation and also regulates the duration of the p53 respo
phorylation status of this residue should greatly facilitate our a
668 Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc.DNA damage induced by ionizing radiation (IR) is a well-
established initiator of p53 activity. Wild-type (WT) mice that
are treated with whole body IR undergo p53-dependent
apoptosis in both radiosensitive tissues such as thymus, spleen,
and small intestine, and in hematopoietic cells (Gudkov and
Komarova, 2003). Mice exposed to 8 Grays (Gy) or more of IR
will die within 3 weeks due to depletion of the hematopoietic
compartment, a condition known as hematopoietic syndrome
(Komarova et al., 2004). In contrast, p53 null mice are more
tolerant of acute radiation, as their hematopoietic cells are less
prone to IR-induced apoptosis. However, p53-deficient mice
will display an increased rate of tumorigenesis following IR
treatment (Kemp et al., 1994).
Because p53-dependent cell cycle arrest and apoptosis are
deleterious to the growth and survival of nondamaged cells,
p53 activitymust be kept atminimal levels under normal, homeo-
static conditions. Although p53 regulation by numerous cellular
proteins has been observed under various experimental condi-
tions, it has become increasingly apparent that the Mdm2the oncogenic transformation of cells exposed to genotoxic
p53 activation during the DNA damage response is crucial to
wild-type p53 alleles have the potential for restoration of p53
t also ameliorate radiation therapy-induced pathologies. Our
uman MDM2 Ser395) is required for DNA damage-induced
nse to DNA damage. Thus, devising means to alter the phos-
bility to regulate p53 activity in normal and neoplastic cells.
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Mdm2-S394 Phosphorylation Regulates p53 In Vivooncoprotein is the chief negative regulator of p53 in damaged
and nondamaged cells (Bond et al., 2005). Mdm2 represses
p53 activity by binding and sequestering p53 away from p53
target gene promoters (Momand et al., 1992; Chen et al.,
1995). Furthermore, Mdm2 contains a RING domain with E3
ubiquitin ligase activity and can ubiquitinate p53, leading to
p53 nuclear export and degradation in the 26S proteasome
(Honda et al., 1997). Interestingly, Mdm2 is a transcriptional
target of p53, and p53 transactivation of Mdm2 expression is
thought to form an autoregulatory feedback loop to limit p53
activity in the cell (Juven et al., 1993; Wu et al., 1993). The impor-
tance of Mdm2-mediated inhibition of p53 signaling has been
demonstrated previously in vivo. Mdm2/ mice die at E5–E6
during development due to aberrant p53-mediated apoptosis
(Jones et al., 1995; Montes de Oca Luna et al., 1995), whereas
Mdm2 overexpression in mice inhibits p53 tumor suppression,
resulting in the formation of lymphomas, soft tissue sarcomas,
and osteosarcomas (Jones et al., 1998). Thus proper regulation
of Mdm2 expression and activity is critical for normal p53
signaling and cellular function.
Activation of p53 in response to DNA damage necessitates
a transient attenuation of Mdm2-dependent p53 inhibition. Post-
translational modifications of the p53 protein by DNA damage-
inducible kinases were initially thought to inhibit the interaction
of p53 andMdm2 (Shieh et al., 1997). The ATM (mutated in ataxia
and telangiectasia) kinase is necessary for p53 stabilization in
tissues such as mouse embryonic fibroblasts (MEFs) andmurine
thymus following IR (Jack et al., 2002; Gurley and Kemp, 2007),
and ATMwill directly and indirectly (via Chk2) phosphorylate p53
on Ser18 and Ser23 in irradiated mice (Ser15 and Ser20 on
human p53) (Chao et al., 2000; Wu et al., 2002). These serine
residues are located within or adjacent to the Mdm2 binding
domain of p53, and initial in vitro studies demonstrated that
phosphorylation of p53 decreased the p53-Mdm2 interaction
in transfection and overexpression experiments (Shieh et al.,
1997). Several groups, including our own, subsequently gener-
ated mouse models bearing modified p53 alleles to examine
the role of these posttranslational modifications in p53 regulation
and function in vivo (Chao et al., 2003, 2006; Sluss et al., 2004).
These studies revealed that phosphorylation of these ATM-
target serines on p53 modulated the transcriptional activity of
p53, but had only a moderate effect on DNA damage-induced
stabilization of the p53 protein.
In addition to modifying p53, transfection-based assays have
revealed that ATM can directly phosphorylate serine 395 of
human MDM2 (Khosravi et al., 1999; Maya et al., 2001). One
study utilized an MDM2 expression construct with the serine
residue 395 codon replaced by sequences encoding aspartic
acid (S395D), thus mimicking a constitutively phosphorylated
serine residue. The MDM2 S395D protein exhibited a decreased
capacity to induce p53 degradation and nuclear export, sug-
gesting that phosphorylation of MDM2 Ser395 altered p53 acti-
vation following DNA damage. Further in vitro work suggested
that ATM phosphorylation of multiple amino acid residues on
MDM2, including Ser395, inhibited both MDM2 RING domain
oligomerization and E3 ligase activity (Cheng et al., 2009,
2011). Interestingly, recent work has indicated that ATM phos-
phorylation of MDM2 switches MDM2 from a negative to a posi-
tive regulator of p53, as phosphorylation of MDM2 Ser395increased the interaction between MDM2 protein and p53
mRNA and led to increased p53 translation (Gajjar et al., 2012).
These transfection-based studies suggest that the ATM-
dependent induction of the p53 protein is mediated by ATM
phosphorylation of MDM2.
In keeping with a role for MDM2 Ser395 phosphorylation in
the p53 DNA damage response, we have previously shown
that the Wip1 oncoprotein can dephosphorylate MDM2
Ser395 in vitro (Lu et al., 2007). Wip1 antagonizes ATM func-
tion by dephosphorylating many known ATM target proteins,
including ATM itself. Therefore, Wip1 has been proposed to
reset DNA damage signaling to prestress levels following
resolution of the DNA damage response (Lu et al., 2008).
Like Mdm2, the Wip1 gene is a direct transcriptional target
of p53, and p53 induction of Wip1 expression might also limit
the p53-dependent DNA damage response. Although the
coincidental timing of MDM2 Ser395 phosphorylation and
dephosphorylation suggests that this modification may
coordinate the p53-dependent response to DNA damage,
the in vivo functional significance MDM2 phosphorylation in
Mdm2-p53 regulation, p53 activation, and in tumorigenesis
remains unknown.
To determine the role of MDM2 Ser395 phosphorylation in p53
regulation under physiological settings, we have generated two
knock-in mouse models bearing Mdm2 Ser394 substitutions
(the orthologous human Ser395 residue in the mouse) and
analyzed the effects of these substitutions on p53-mediated
DNA damage response and tumor suppression.
RESULTS
To investigate the role of Mdm2 Ser394 phosphorylation under
physiological conditions, we generated a mouse model in which
this serine residue is substituted with an alanine residue (S394A).
This model produces a mutant Mdm2 protein with a conserved
native structure that cannot be phosphorylated at position 394.
Site-directed mutagenesis was performed to introduce
missense mutations within the 394 codon of Mdm2 exon 12,
and a gene-replacement vector was constructed to replace the
endogenous Mdm2 exon 12 sequences with a mutated exon
12 (Figure 1A). The introduced mutations also inserted a novel
BcgI restriction digest site at codon 394, which allows direct
detection of the mutated sequence by a PCR strategy. Gene
targeting experiments in PC3 (129SV) embryonic stem (ES) cells
(O’Gorman et al., 1997) yielded properly-targeted ES cell clones,
as confirmed by Southern and PCR analyses (Figures S1A–S1C
available online). Blastocyst injection experiments produced
several high-degree male chimeras that passed the S394A allele
through their germ line while simultaneously deleting the floxed
neomycin cassette due to expression of the protamine-Cre
transgene (present in the PC3 ES cells). The resultant F1 and
F2 generation mice were identified by Southern blot of genomic
DNA (Figure S1D). The presence of the S394Amutation in these
mice was confirmed by utilizing the PCR-BcgI digest strategy
(Figure 1B). This corroborated the Southern genotyping results
and demonstrated retention of the mutation in both heterozy-
gous (A/+) and homozygous (A/A) mice. All genotyping tech-
niques were reaffirmed by direct genomic sequencing of the
exon 12 region in F1 and F2 mouse genomic DNA (Figure S1E).Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc. 669
Figure 1. Phosphorylation of Mdm2 Ser394 Regulates Radiosensitivity in Mice
(A) DNA sequence of the WT and S394A alleles at Mdm2 codon 394. The mutations in S394A also introduce a BcgI restriction digest site.
(B) PCR-BcgI analysis of F2 generation mice. Primers flankingMdm2 codon 394 were used to amplify DNA samples fromWT, A/+, and A/A F2 generation mice,
followed by BcgI digestion.
(C) Mice that are either heterozygous and homozygous for the S394A allele are viable and were observed at Mendelian ratios after heterozygous intercrosses (p =
0.322).
(D) Cohorts of wild-type (n = 14), A/A (n = 14), and p53/ (n = 8) mice were irradiated with 8Gy and survival was observed over 26 days.
(E)WT,A/A, and p53/micewere irradiatedwith 2Gy andwere sacrificed 6 hr later. Small intestine, spleen, and thymuswere harvested and stained for TUNEL or
anti-cleaved caspase-3 (Casp-3). Scale bars represent 250 mm.
See also Figure S1.
Cancer Cell
Mdm2-S394 Phosphorylation Regulates p53 In VivoA/+ and A/Amice are viable and were recovered from hetero-
zygous intercrosses at Mendelian ratios (Figure 1C). Because
Mdm2/ mice are embryonic lethal (Jones et al., 1995; Montes
de Oca Luna et al., 1995), total ablation of Mdm2 function during
development must not be occurring in A/+ or A/Amice. We also
did not detect any differences between WT and A/A mice in
body weights at 8 weeks of age (WT 25.67 ± 2.9 g and A/A
24.3 ± 4.2 g), in male-to-female sex distribution (WT 1:0.82
and A/A 1:0.90), or in overall litter size (WT 8.5 ± 1.8 and A/A
8.7 ± 1.9). Because mice with decreased p53 function have
decreased fecundity (Levine et al., 2011), our results suggest
that basal p53 activity is not perturbed in A/A mice.
Because ATM phosphorylation of MDM2 Ser395 was previ-
ously observed in cell lines following IR treatment (Maya et al.,
2001), we assessed the sensitivity of A/A mice to whole body
g-irradiation. We irradiated cohorts of WT, A/A, and p53/
mice with a threshold-lethal dose of IR (8Gy). As expected,
86% of wild-type mice died by 16 days post-IR (Figure 1D).
However, like p53/ mice, A/A mice were completely radiore-
sistant, indicating that Mdm2 Ser394 phosphorylation regulates
p53 activity in vivo following DNA damage. Activation of p53
by IR damage in mice induces apoptosis in radiosensitive
organs such as small intestine, spleen, and thymus (Gudkov
and Komarova, 2003). To evaluate p53 apoptotic function in
these tissues, we treated WT, A/A, and p53/ mice with 2Gy
IR and 6 hr later assayed apoptosis by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and cleaved670 Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc.caspase-3 immunohistochemistry (Figure 1E). Very few
apoptotic cells were detected in the small intestine, spleen, or
the thymus of A/A mice following DNA damage, whereas
apoptosis was readily apparent in all of these tissues in irradiated
wild-typemice. As expected, little or no apoptosis was observed
in tissues of IR-treated p53/ control mice, and apoptosis was
not detected in the untreated animals, regardless of genotype
(Figure S1F). These studies indicate markedly reduced p53-
dependent apoptotic function in A/A mice after IR treatment.
To more accurately quantitate this IR-dependent effect, we
utilized Annexin V and propidium iodide (PI) staining to assay
apoptosis in ex vivo thymocytes by flow cytometry (Figure S2A).
Wild-type thymocytes are sensitive to apoptosis due to p53-
induced activation of proapoptotic Puma expression (Jeffers
et al., 2003). In agreement with the whole-body IR results, WT
thymocytes treated with 2Gy IR displayed 3.1-fold more early
apoptotic (Annexin Vhigh PIlow) cells at 12 hr compared to
untreated WT cells, whereas A/A thymocytes displayed only
a modest 1.5-fold increase in apoptotic cells and p53/ thymo-
cytes showed no induction of apoptosis after DNA damage
(Figure 2A).
To establish that the decreased apoptosis in DNA damaged
A/A thymocytes is due to altered p53 function, we treated WT,
A/A, and p53/ thymocytes with Nutlin-3a, a small-molecule
inhibitor of Mdm2-p53 binding (Vassilev et al., 2004). WT and
A/A thymocytes cotreated with Nutlin-3a and IR each stabilized
p53 after IR damage (Figure 2B), and blocking the interaction of
Figure 2. ATM Phosphorylation of Mdm2 Ser394 Promotes p53-Dependent Apoptosis after DNA Damage
(A) Ex vivo thymocytes were either left untreated or irradiated with 2Gy for 12 hr and apoptotic cells were quantified by flow cytometry (n = 3 per genotype).
Standard deviation indicated by error bars. Asterisk (p = 0.0001) and double asterisk (p = 0.0001) indicate significant differences.
(B) Ex vivo thymocytes were either untreated or irradiated with 2Gy for 1 hr, and all cells were then incubated with 12 mM Nutlin-3a for 1 hr. Protein levels were
analyzed by western blot.
(C) Ex vivo thymocytes were either left completely untreated or irradiated with 2Gy for 12 hr and incubated with 12 mMNutlin-3a 3 hr after IR (9 hr total) (n = 3 per
genotype). Apoptotic cells were quantified by flow cytometry Standard deviation indicated by error bars.
(D) Ex vivo thymocytes were preincubated with 10 mM KU55933 for 1 hr. Cells were then either left untreated or irradiated with 2Gy for 12 hr and apoptotic cells
were quantified by flow cytometry (n = 3 per genotype). Standard deviation indicated by error bars.
(E) Ex vivo thymocytes were either left untreated or preincubated with 10 mMKU55933 for 1 hr. Cells were then either untreated or irradiated with 2Gy for 2 hr, and
protein levels were analyzed by western blot.
See also Figure S2.
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Mdm2-S394 Phosphorylation Regulates p53 In Vivop53 with Mdm2-S394A completely rescued the ability of p53
to induce apoptosis in A/A thymocytes following DNA damage
(Figure 2C). To confirm that Nutlin-3a treatment restored IR-
induced apoptosis inA/A cells by inhibitingMdm2-p53 signaling,
we performed FACS analysis on A/A thymocytes that were
genetically deleted for p53. As expected, the addition of Nut-
lin-3a failed to restore IR-induced apoptosis in A/A cells lacking
p53 (Figure S2B).
To verify that the effect of the Mdm2 S394A mutation on IR-
apoptosis was truly ATM-dependent, we repeated the apoptosis
assays using the ATM-specific inhibitor KU55933 (Hickson et al.,
2004). Inhibition of ATM reduced apoptosis in irradiated thymo-
cytes to levels observed in untreated cells in all genotypes
(Figure 2D). Additionally, the ATM inhibitor blocked the robust
ATM activation and p53 protein stabilization induced by IR
damage (Figure 2E).
To further investigate the lack of IR-induced p53 function in
A/A mice, we compared the stabilization and activity of p53 in
WT and A/A radiosensitive tissues after DNA damage. We first
harvested whole spleen protein extracts 4 hr after whole-body
IR treatment. As expected, activation of the ATM kinase in
wild-type mice by 4Gy IR was readily detected, as judged by
the extent of autophosphorylated ATM Ser1987, the mouse or-
tholog of human ATM Ser1981 (Pellegrini et al., 2006), and this
tissue displayed robust IR-stabilization of p53 (Figure 3A).
However, A/A mice lack any detectable stabilization of the p53protein, despite comparable activation of ATM by IR. This lack
of p53 protein upregulation in IR-treated A/A spleen extracts
was seen in multiple mice (Figure S3A), and corresponded with
greatly decreased induction of the p53-target genes Puma,
p21, Bax, and Noxa, as measured by quantitative real time
PCR (qRT-PCR) (Figure 3B). However, IR-treated A/A spleens
did show a low-level activation of p53, as expression of p53
target genes was slightly elevated relative to levels in IR-treated
p53/ spleens.
Similar results were seen at multiple time points in thymus
extracts following whole-body IR treatment of mice (Figures 3C
and S3B). The level of p53 protein in wild-type thymus was upre-
gulated by 6.4-fold (1 hr), 4.8-fold (2 hr), and 1.8-fold (4 hr)
following 4Gy IR, whereas p53 levels in IR-treated A/A thymus
were upregulated by only 2.1-fold, 1.3-fold, and 1.2-fold at these
respective time points (Figure 3C). Again, these differences were
seen despite similar activation of the ATM kinase. As observed in
spleen, expression of the p53-target genes Puma and p21 were
significantly reduced in A/A thymus at all time points after IR
treatment (Figure 3D). Because the p53 protein is phosphory-
lated by ATMon p53 Ser18 in the treatedA/A thymus (Figure 3C),
the reduced levels of p53 target gene expression in this tissue
are likely due to decreased p53 protein stabilization in A/A
mice after IR, and not due to failure of ATM to induce proper
posttranslational modification of p53. Analysis of multiple p53
target genes in irradiated WT and A/A thymocytes using p53Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc. 671
Figure 3. Mdm2 Ser394 Phosphorylation Is
Necessary for p53 Stability and Activity after
DNA Damage
(A) Mice were either untreated or irradiated with
4Gy and spleens were harvested 4 hr later. Protein
levels were then analyzed by western blot.
(B) Mice were either untreated or irradiated with
4Gy and spleens were harvested 4 hr later (n = 3
per genotype). Relative expression levels of p53
target genes in irradiated spleen extracts were
determined by qRT-PCR. Levels were normalized
to untreated wild-type and are presented as the
ratio of mRNA to Gapdh mRNA. Standard
deviation indicated by error bars. Asterisks
indicate a significant difference: double asterisk
Puma p = 0.002, p21 p = 0.01,Bax p = 0.003,Noxa
p = 0.002; single asterisk Puma p = 0.01, p21
p = 0.001, Bax p = 0.01, Noxa p = 0.008.
(C) Mice were either untreated or irradiated with
4Gy and thymi were harvested at the indicated
times. Protein levels were then analyzed by
western blot.
(D) Mice were either untreated or irradiated with
4Gy and thymi were harvested 2 or 4 hr later (n = 3
per genotype). Relative expression levels of p53
target genes were determined by qRT-PCR. Data
are presented as the ratio of mRNA to Gapdh
mRNA. Standard deviation indicated by error bars.
Significant differences were seen between WT
and A/A Puma at 2 (p = 0.035) and 4 (p = 0.002) hr
and betweenWT andA/A p21 at 2 (p = 0.0001) and
4 (p = 0.0001) hr.
(E) Protein levels from whole thymus extracts from
untreated mice were analyzed by western blot
(n = 3 per genotype). Quantified levels of p53
(p = 0.83) and Mdm2 (p = 0.11) relative to PI3K
were normalized to wild-type.
(F) Mice were either untreated or irradiated with
4Gy and thymi were harvested at the indicated
times. Protein levels were then analyzed by
western blot. Quantified levels of p53 and Mdm2
relative to PI3K were normalized to untreated
wild-type.
See also Figure S3.
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Mdm2-S394 Phosphorylation Regulates p53 In Vivosignaling pathway PCR arrays confirmed reduced activation of
multiple p53 target genes in treatedA/A cells (Figure S3C). These
results reveal that Mdm2 Ser394 phosphorylation is required
in vivo for p53 stabilization and robust p53 activation after DNA
damage.
Mdm2 destabilization in response to DNA damage has been
shown previously (Stommel and Wahl, 2004), and we observed
an initial decrease in Mdm2 protein in bothWT and A/A tissues.
Interestingly, these Mdm2 levels recovered at 2 and 4 hr in both
genotypes, with more Mdm2 protein being present in WT at
these times compared to A/A (Figure 3C). To determine if the
initial decrease in Mdm2 levels was due to epitope masking by
IR-induced phosphorylation, we treated these extracts with
calf intestinal phosphatase (CIP); however, this treatment neither
increased nor altered the pattern of Mdm2 levels after DNA
damage (Figure S3D). Interestingly, the phosphorylation status
of Mdm2 Ser394 had no effect on the levels of MdmX, an
Mdm2-related p53 regulatory protein, in this tissue. The specific-
ities of the Mdm2 and MdmX antibodies were validated using672 Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc.Mdm2/, MdmX/, p53/ triple-knockout (TKO) thymus
extracts (Figure S3E).
We next wanted to determine why differences in p53 and
Mdm2 levels are observed in irradiated WT versus A/A cells.
One possibility is that p53 and Mdm2 protein levels are initially
lower in A/A cells than inWT cells, leading to an overall reduced
DNA damage response in A/A mice. To test this, we carefully
quantitated p53 and Mdm2 protein levels in untreated WT and
A/A whole thymus extracts and found no significant difference
in the levels of either p53 or Mdm2 proteins at baseline
(Figure 3E). These data support the similar baseline levels of
apoptosis and gene expression that we observed in WT and
A/A tissues in the absence of DNA damage (Figures 2 and 3E).
Furthermore, careful quantitation confirmed that there is less
p53 protein and Mdm2 protein in A/A thymus than inWT thymus
after IR (Figure 3F). Because baseline Mdm2 levels were equiv-
alent in A/A and WT tissue, the reduced amount of Mdm2 and
p53 in A/A versus WT tissues reflects a specific difference in
the response of A/A cells to DNA damage.
Figure 4. Phosphorylation of Mdm2 Ser394 Does
Not Significantly Impact Mdm2 Destabilization
after DNA Damage
(A) Ex vivo thymocytes were either untreated or irradiated
with 2Gy for the indicated times. Protein levels were then
analyzed by western blot.
(B) Ex vivo thymocytes were either untreated or irradiated
with 2Gy for the indicated time points (n = 3 per geno-
type). Relative expression levels of Mdm2 were deter-
mined by qRT-PCR. Data are presented as the ratio of
mRNA to Gapdh mRNA. Standard deviation indicated by
error bars.
(C) Ex vivo thymocytes were incubated with 50 mg/ml of
CHX and either left untreated or irradiated with 2Gy for the
indicated times. Protein levels were then analyzed by
western blot. Quantified levels of Mdm2 relative to PI3K
were normalized to untreated wild-type.
See also Figure S4.
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Mdm2-S394 Phosphorylation Regulates p53 In VivoTo further examine the effects of Mdm2 Ser394 phosphoryla-
tion on p53 and Mdm2 stability, we performed western blots
using irradiated WT and A/A ex vivo thymocytes. Stabilization
of p53 was detected in primary wild-type thymocytes at 1–2 hr
post-IR, and p53 levels remained elevated in these cells 6 hr after
IR damage (Figures 4A and S4). In contrast, p53 stabilization was
not apparent in A/A thymocytes at these early time points after
DNA damage, even though ATM was clearly activated by IR
treatment. Similar to whole thymus extracts, Mdm2 levels also
appear decreased in irradiated A/A thymocytes compared to
IR-treated WT cells. The increased levels in wild-type Mdm2
protein may be due to increased p53-induced Mdm2 transcrip-
tion, and indeed, like other p53-dependent targets, Mdm2 tran-
scripts are lower in the irradiated A/A thymocytes (Figure 4B).
Alternatively, the difference in Mdm2 protein levels after DNA
damage may be due to decreased Mdm2 protein stability in
A/A thymocytes compared to WT cells. To examine the effects
of Mdm2 Ser394 phosphorylation on Mdm2 stability in vivo, we
incubated untreated and irradiated WT and A/A thymocytes
with the protein synthesis inhibitor cycloheximide (CHX).
Although Mdm2 protein is relatively unstable in thymocytes, we
found that IR treatment lead to further decreases in Mdm2
stability in both genotypes (Figure 4C). However, the stability of
Mdm2 proteins in untreated and IR-treated WT and A/A thymo-
cytes was comparatively indistinguishable. Therefore, our
results indicate that the lower Mdm2 protein levels in A/A thymo-
cytes after DNA damage reflects less p53 activation of Mdm2
transcription in these cells and not reduced Mdm2-S394A
protein stability.
The reduced p53 transactivation of p21 observed in the spleen
and thymus of IR-treated A/A mice (Figure 3) suggests that
Mdm2 Ser394 phosphorylation may also impact p53 regulation
of cell proliferation. To examine this further, we assayed p53
function in WT and A/A MEFs. No difference in the growth rate
of A/A or WT cells was observed using a standard proliferation
assay (Figure 5A). This result is in keeping with the equivalent
low levels of p53 observed in nondamaged WT and A/A tissues
(Figure 3). However, greater p53 protein stabilization was
observed in WT MEFs than in A/A MEFs at 6 and 12 hr post-IR
(Figure 5B). Likewise, transactivation of p21 was greater in WT
MEFs than in A/A cells, and induction of Mdm2 transcripts wasdelayed in A/A MEFs (Figure 5C). FACS analysis of WT, A/A,
and p53/MEFs at 18 and 45 hr post-IR revealed that A/A cells
are compromised in their ability undergo growth arrest after DNA
damage (Figure 5D). However, as compared to p53/ cells, the
A/AMEFs do retain the ability to undergo a partial growth arrest
after IR damage. Additionally, no differences were observed in
the nuclear versus cytoplasmic fraction of Mdm2 protein in A/A
and WT MEFs before or after DNA damage (Figure S5). These
data reveal that phosphorylation of Mdm2 Ser394 also governs
the ability of Mdm2 to regulate p53-mediated cell growth arrest
after IR.
Because ATM phosphorylation of Mdm2 Ser394 is necessary
for robust p53 activation after DNA damage, we wanted to test
whether this posttranslational modification alone was sufficient
to induce p53 activity in untreated tissues. To this end, we gener-
ated a different mouse model in which Mdm2 Ser394 was
mutated to aspartic acid (S394D), thusmimicking a constitutively
phosphorylated serine residue (Figure 6A). We followed the
same gene replacement strategy used to generate the S394A
model (Figures S6A–S6D). We hypothesized that if phosphoryla-
tion of Mdm2 Ser394 is sufficient by itself to disrupt Mdm2 regu-
lation of p53, then substitution of aspartic acid at codon 394
might lead to embryonic lethality in mice bearing functional
p53 alleles (as is seen inMdm2 null mice). However, both hetero-
zygous (D/+) and homozygous (D/D) mice proved to be viable,
and both genotypes were recovered from heterozygous inter-
crosses at Mendelian ratios (Figure S6E). The viability of this
knock-in mutant suggests that baseline levels of p53 protein
would be unchanged in this model compared to controls, and
subsequent quantitation of p53 and Mdm2 protein levels in
untreated thymus protein extracts revealed no significant differ-
ences between WT and D/D (Figure 6B).
The viability of D/D mice also suggests that either multiple
DNA damage signals are needed to attenuate Mdm2 regulation
and activate p53, or that the Mdm2 S394D mutation poorly
mimics a phosphoserine residue. The latter possibility would
result in D/D mice presenting with phenotypes similar to our
A/Amodel, because aspartic acid (like alanine) cannot be phos-
phorylated. To test this, we treated WT and D/D mice with 4Gy
whole-body irradiation and examined p53 stabilization in thymus
cells at various early time points after DNA damage. In contrastCancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc. 673
Figure 5. Mdm2 Ser394 Phosphorylation Is
Necessary for Full p53 Stabilization and
Function in MEFs
(A) Primary MEFs proliferation was counted each
day (n = 3 per genotype). Standard deviation
indicated by error bars.
(B) Primary MEFs were either untreated or irradi-
ated with 4Gy for the indicated times, and protein
levels were then analyzed by western blot.
(C) Primary MEFs were either untreated or irradi-
ated with 4Gy for the indicated times (n = 3 per
genotype). Relative expression levels of p53 target
genes were determined by qRT-PCR. Data are
presented as the ratio of mRNA to Gapdh mRNA.
Standard deviation indicated by error bars.
(D) Primary MEFs were treated with 4Gy IR for the
indicated time points and then incubated with
bromodeoxyuridine (BrdU) for 3 hr (n = 3 per
genotype). Cells were then analyzed by flow cy-
tometry. Standard deviation indicated by error
bars. Asterisks indicate a significant difference:
double asterisk 18 hr p = 0.0318, 45 hr p = 0.0126;
single asterisk 18 hr, p = 0.0004, 45 hr p = 0.0001.
See also Figure S5.
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Mdm2-S394 Phosphorylation Regulates p53 In Vivoto what we observed in A/A cells, p53 protein stabilization by IR
damage in D/D thymus extracts was comparable to wild-type
(Figure 6C). This was also observed in IR-treated ex vivo thymo-
cytes (Figure S6F). Likewise, the pattern of Mdm2 protein desta-
bilization followed by recovery was equivalent between the WT
and D/D tissues (Figure 6C), which reflects the equal induction
of Mdm2 transcript levels seen in DNA damaged thymocytes
(Figure 6D). Puma transcript levels were also similarly increased
in the IR-treated WT and D/D cells (Figure 6D), and the levels of
DNA damage-induced apoptosis were the same between WT
and D/D thymocytes at 12 hr after IR treatment (Figure 6E).
Similar results were obtained in thymocytes at 24 hr post-IR
(Figure S5G), as well as in thymocytes isolated 48 hr after
whole-body IR in WT, D/D, and p53/ mice (Figure S5H).
Collectively, these findings demonstrate that Mdm2 S394D
mimics the effects of the phosphorylated Mdm2 Ser394 protein
in wild-type mice after DNA damage. As baseline levels of p53
protein and apoptosis in nondamaged WT and D/D cells are
the same in these assays, the mimicking of Mdm2 Ser394 phos-
phorylation in D/D thymocytes is not sufficient in the absence of
other DNA damage-induced signals to induce p53 activation.
To confirm the effects of this Mdm2 Ser394 phospho-mimic in
cell growth, WT and D/D MEFs were analyzed for cell prolifera-
tion (Figure 6F). As with A/A MEFs, the D/D MEFs proliferated
at the same rate as wild-type MEFs in culture. However, IR-
treatment of D/DMEFs induced p53 stabilization at levels similar
to IR-treated WT MEFs (Figure 6G), and IR damage induced an
equivalent p53-mediated reduction in S phase in both WT and
D/D cells (Figure 6H).
Previous in vitro work has established that the Wip1 phospha-
tase can dephosphorylate multiple ATM targets, including
human ATM Ser1981, p53 Ser15, and MDM2 Ser395 (Shreeram
et al., 2006; Lu et al., 2005, 2007). This dephosphorylation has
been proposed to return DNA damage signaling to basal levels
once the DNA damage has been resolved. BecauseWip1 cannot
dephosphorylate the Mdm2-S394D residue, we hypothesized674 Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc.that D/D and WT mice might have differences in the duration of
Mdm2-p53 signaling after IR treatment. Therefore, we analyzed
p53 stabilization and activity at later time points in the DNA
damage response. Like D/D thymocytes (Figure S6F), WT and
D/D spleen samples had equal levels of ATM activity and p53
levels at 4 hr post-IR. However, the level of p53 protein remained
persistently elevated at 8 hr post-IR in D/D extracts, despite the
reduction in ATM activity and similar levels of Mdm2 by this later
time point (Figures 7A and S7A). A similar response pattern was
seen in primary thymocytes. Although p53 was stabilized to
a similar extent in WT and D/D mice at early time points after
IR damage (see Figure 6C), p53 levels remain elevated in D/D
thymocytes at 12 hr post-IR, whereas p53 stabilization is less
obvious at this later time point in wild-type cells (Figure 7B). As
in spleen, the elongated duration of p53 stabilization in D/D
thymocytes was seen well after resolution of the DNA damage
response, as indicated by the absence of phospho-ATM at
12 hr post-IR, and despite the presence of Mdm2. The elongated
p53 response in D/D thymocytes was reflected by increased
levels of Puma, p21,Mdm2, andWip1 expression found in these
cells at 12 and 18 hr post-IR (Figure 7C), and p53 signaling
pathway PCR array analysis of additional p53 target genes
confirmed that p53 activation remained elevated in D/D thymo-
cytes relative to wild-type levels at 12 hr following IR
(Figure S7B).
Finally, to explore the importance of Mdm2 Ser394 phosphor-
ylation in p53-mediated tumor suppression, we established
cohorts ofWT, A/A, andD/Dmice and performed a tumor assay.
In 24 months, 20 of 31 (65%) A/A mice developed spontaneous
tumors, whereas only 1 of 24 (4%) D/D mice presented with
a tumor of the salivary gland epithelium (Figure 8A). None of
the wild-type mice presented with a tumor during this interval.
Most of the A/A tumors arose between 18–24 months of age,
which closely resembles previous p53+/ tumor curves (Harvey
et al., 1993; Jacks et al., 1994). Like other mouse models with
diminished p53 activity, most of the tumors (13/20; 65%) were
Figure 6. Phosphorylation of Mdm2 Ser394 Is Necessary But Not Sufficient to Stabilize and Activate p53
(A) DNA sequence of both the WT and S394D allele at Mdm2 codon 394. The mutations in S394D also introduce a BclI restriction digest site.
(B) Protein levels from whole thymus extracts from untreated mice were analyzed by western blot (n = 3 per genotype). Quantified levels of p53 (p = 0.10) and
Mdm2 (p = 0.88) relative to PI3K were normalized to wild-type.
(C) Mice were either untreated or irradiated with 4Gy and thymi were harvested at the indicated times. Protein levels were then analyzed by western blot.
Quantified levels of p53 and Mdm2 relative to PI3K were normalized to untreated wild-type.
(D) Ex vivo thymocytes were either untreated or irradiated with 2Gy for 2 or 4 hr (n = 3 per genotype). Relative expression ofMdm2 and Pumawas determined by
qRT-PCR. Data are presented as the ratio of mRNA to Gapdh mRNA. Standard deviation indicated by error bars.
(E) Ex vivo thymocytes were isolated and were either left untreated or irradiated with 2Gy for 12 hr (n = 3 per genotype). Apoptotic cells were quantified by flow
cytometry. Standard deviation indicated by error bars.
(F) Primary MEF proliferation was counted each day (n = 3 per genotype). Standard deviation indicated by error bars.
(G) Primary MEFs were either untreated or irradiated with 4Gy for the indicated times, and protein levels were analyzed by western blot.
(H) Primary MEFs were treated with 4Gy IR for 18 hr or 8Gy IR for 45 hr and incubated with BrdU for 3 hr (n = 3 per genotype). Cells were then analyzed by flow
cytometry. Standard deviation indicated by error bars.
See also Figure S6.
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morphology, negative staining for the B cell marker B220, and
positive staining for the T cell marker CD3 (Figure 8B, left panels).
The remaining A/A tumors displayed severe splenomegaly and
cellular infiltration in the liver and kidneys. One of these tumors
stained positive for B220 and displayed expansion of the white
pulp in the spleen, indicative of B cell lymphoma (Figure 8B, right
panels). Sequencing of p53 transcripts isolated from four
randomly selected tumors indicated wild-type p53 expression
levels and no p53mutations in these A/A samples. These results
reveal that posttranslational modification of Mdm2 Ser394
impacts p53-mediated tumor suppression as well as the p53
DNA damage response in vivo.
DISCUSSION
In our present study utilizing mouse models of Mdm2 Ser394
phosphorylation, we provide direct evidence that ATM phos-
phorylation of Mdm2 Ser394 regulates the ability of Mdm2 to
destabilize p53 in vivo, and that this signaling impacts p53-
mediated apoptosis and tumor suppression. S394A mice lackp53-dependent physiological responses in radiosensitive
organs after IR treatment resulting in phenotypes that nearly
match those seen in IR treated p53/ mice: radioresistance,
greatly reduced p53 target gene induction, and greatly reduced
apoptosis. Importantly, the differences between A/A and WT
mice were seen only in irradiated mice and tissues, as baseline
levels were similar in all assays. This owes to the conservation
of Mdm2 structure and function in the S394A protein, and indi-
cates that the only difference between the wild-type and mutant
Mdm2 protein is the phosphorylation status of Ser394 after
cellular stress. It is likely that the compromised p53 transactiva-
tion and the reduced number of cells undergoing apoptosis and
cell cycle arrest are due to the lack of p53 protein accumulation
in DNA damaged A/A cells. Thus, phosphorylation of Mdm2
Ser394 by the ATM kinase is a major regulator of p53 stability
and the subsequent p53-mediated DNA damage response in
multiple tissue types.
Although loss of Mdm2 Ser394 phosphorylation greatly
reduced p53-mediated apoptosis in lymphocytes and growth
arrest in MEFs, it did not completely abrogate these responses
(as seen in p53/ mice). As anticipated by the literature, otherCancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc. 675
Figure 7. Mdm2 Ser394 Phosphorylation Regulates the Attenuation of the p53 Response to DNA Damage
(A) Mice were either untreated or irradiated with 4Gy and spleens were harvested either 4 or 8 hr later. Protein levels were then analyzed by western blot.
(B) Ex vivo thymocytes were either untreated or irradiated with 2Gy for either 12 or 18 hr. Protein levels were then analyzed by western blot.
(C) Ex vivo thymocytes were either untreated or irradiated with 2Gy for the indicated times (n = 3 per genotype). Relative expression levels of p53 target genes
were determined by qRT-PCR. Data are presented as the ratio of mRNA to Gapdh mRNA. Standard deviation indicated by error bars.
See also Figure S7.
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lating p53 functions after DNA damage (Chao et al., 2003, 2006;
Sluss et al., 2004; Wang et al., 2009). In agreement with this
hypothesis, it is interesting to note the lack of p53 stabilization
or p53 target gene activation in D/D mice and cells in the
absence of IR treatment (Figures 6B–6D). Although the absence
of a p53 response in undamaged D/D cells may reflect the
inability of the substituted aspartate residue to perfectly mimic
a phosphorylated serine residue (due to differences in the size
and overall negative charge of these residues), equivalent levels
of p53-mediated apoptosis and growth arrest are seen inWT and
D/D cells after DNA damage. Therefore, other DNA-damage
induced signals in addition to Mdm2-S394 phosphorylation are
required to fully activate the DNA damage response. This inter-
pretation also accounts for the viability of the S394D model,
and the similar growth characteristics of nondamaged WT,
A/A, and D/D MEFs. Collectively, our results indicate that ATM
phosphorylation of Mdm2 Ser394 is necessary but not sufficient
to induce a robust p53 response to IR.
Although the levels of p53 induction and activation are equiv-
alent at early time points after IR in WT and D/D cells, p53
protein levels and activities remain elevated in D/D cells at later
time points after IR treatment (Figures 7 and S7). In contrast,
the DNA damage response in wild-type cells begins to wane
after 6 hr post-IR, coincident with the induction of Wip1
expression (Figures 7B and 7C). Because Wip1 is unable to
dephosphorylate the Mdm2 S394D residue, elevation of p53
functions in D/D cells at later time points after IR indicates
that Mdm2-S394 phosphorylation also regulates the duration
of the p53 response. However, p53 levels and activities even-
tually return to baseline in the D/D cells, possibly due to the
eventual loss of other secondary modifications to Mdm2 or
p53. These findings are in keeping with a proposed role for676 Cancer Cell 21, 668–679, May 15, 2012 ª2012 Elsevier Inc.Wip1 as gatekeeper of the Mdm2-p53 autoregulatory loop
(Lu et al., 2007).
Interestingly, p53 tumor suppressor function is deficient in
untreated A/A mice, as 65% of these mice developed sponta-
neous lymphomagenesis in the absence of exogenous IR treat-
ment. Because our data indicate that p53 levels and activities
are identical between WT and A/A cells in the absence of DNA
damage, the stochastic nature of endogenous DNA damage
signaling arising from inappropriate oncogene activation or
DNA replication errors may account for this rather long latency
period. Tumor formation in our A/A model is in keeping with
previous reports of a role for ATM-p53 signaling and p53 activa-
tion of theproapoptotic genePuma in p53-mediated suppression
of lymphoma formation (Jeffers et al., 2003; Sluss et al., 2010).
Likewise, the reduced capacity of p53 to suppress growth after
DNAdamage inA/A cellsmay also contribute to the spontaneous
tumorigenic phenotype of A/A mice. It remains to be seen if
phosphorylation of Mdm2 Ser394 by ATM also regulates p53-
mediated suppression of tumors induced by sublethal doses of
radiation or the forced expression of activated oncogenes.
Transfection-based experiments have determined that muta-
tion of six separate ATM phosphorylation sites in the carboxy-
terminus of MDM2, including Ser395, alters MDM2 protein
oligomerization, E3-ligase activity, and the interaction of
MDM2 with p53 (Cheng et al., 2009, 2011). Because p53 activity
is not totally ablated in the A/A model, these additional ATM
targets on Mdm2 may contribute to full p53 activation after
DNA damage. Furthermore, a recent study found that ATMphos-
phorylation of MDM2 Ser395 led to increased p53 mRNA trans-
lation, which suggests that MDM2 may be necessary for p53
protein upregulation after DNA damage (Gajjar et al., 2012).
Diminished Mdm2 E3 ligase activity and phospho-Mdm2-
dependent upregulation of p53 would each explain the
Figure 8. Phosphorylation of Mdm2 Ser394 Impacts p53 Tumor
Suppression in Mice
(A) Spontaneous tumorigenesis in wild-type (n = 50), A/A (n = 31), and D/D
(n = 24) mice.
(B) Representative tumor sections from an A/A T cell lymphoma (mesenteric
lymph node, left) and an A/A B cell lymphoma (spleen, right). Tissue sections
were stained with hematoxylin and eosin (H&E), anti-CD3, or anti-B220. Scale
bars represent 100 mm.
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and activities in the absence of increased Mdm2 protein in IR-
treated A/A thymus extracts. These mechanisms would also
explain the increased p53 activation at later times of the DNA
damage response in D/D cells despite nearly equivalent levels
of Mdm2 compared to wild-type. Our in vivo data are in keeping
with both of these proposed models and confirm a significant
role for Mdm2 S394 phosphorylation in the p53 DNA damage
response.
In conclusion, our study reveals that ATM phosphorylation of
Mdm2 at serine residue 394 is a critical regulator of Mdm2-p53
signaling. Phosphorylation of this Mdm2 residue by ATM
following DNA damage is necessary for p53 stabilization,
thereby upregulating p53 activity and activating p53 down-
stream functions in primary cells and tissues. Furthermore, the
phosphorylation status of Mdm2 Ser394 governs the duration
of the p53 response, underscoring the importance of this single
phosphorylation target in regulating Mdm2-p53 signaling and
p53-mediated tumor suppression. Full understanding of themultiple posttranslational modifications that influence p53
signalingwill likely assist in developing bettermolecular diagnos-
tics and therapeutics for human cancer patients.
EXPERIMENTAL PROCEDURES
Generation of S394A and S394D Mice
The targeting constructs contain a subcloned fragment of theMdm2 genomic
sequence (129Sv strain). Site-directed mutagenesis was performed (Strata-
gene #200523). The targeting vectors were sequenced to ensure that no
unwanted mutations were introduced. PC3 ES cells were electroporated
with each targeting vector. Homologous recombination was detected by
Southern blot using 50 and 30 external probes after SpeI and BamHI restriction
digests, respectively. Targeted cells were microinjected into E3.5 blastocysts
(C57BL/6 strain), and the embryos were surgically implanted into pseudopreg-
nant foster mice by standard procedures. Transmission of the knock-in allele
and excision of the neo cassette in F1 offspring of male chimeric mice was
confirmed by digestion with EcoRI followed by Southern analysis using a 30
internal probe described previously (Steinman and Jones, 2002).
Mice
All mice used in this study were on a mixed 129Sv 3 C57Bl/6 background.
Genomic PCR followed by either BcgI (S394A) or BclI (S394D) digestion was
used to identify inheritance of the mutant alleles. Sequencing of DNA samples
was performed by Sequegen. All mice and cells were irradiated with a cesium-
137 source (Gammacell 40). Animals in the spontaneous tumor cohorts or IR-
treated cohorts were killed if tumor burden was apparent or when moribund.
Animals were maintained and used in accordance with federal guidelines
and those established by the Institutional Animal Care and Use Committee
at the University of Massachusetts Medical School.
Histology
Tissues were fixed in 10% formalin. Irradiated tissue sections (5 mm) were
stained with anti-cleaved caspase-3 antibody (Cell Signaling #9661) or stained
for TUNEL using the In Situ Cell Death Detection Kit, POD (Roche
11684817910). Tumor samples were stained with anti-CD3 (Abcam
ab16044) or anti-CD45R/B220 (BD Pharmingen). All staining was performed
by the UMMS Diabetes and Endocrinology Research Center Morphology
Core.
Western Blotting and Reagents
Tissues and cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl, pH 7.5;
150 mM NaCl; 0.5% NP-40; 20% glycerol) supplemented with 13 protease
inhibitor cocktail (Roche). Protein extracts were analyzed by standard western
blotting with the following antibodies: p53 (1C12), phospho-Atm Ser1987
(10H11.E12), and phospho-p53 Ser18 (#9284) from Cell Signaling; Mdm2
(mix of sc-812 and sc-1022) and lamin A/C (sc-6215) from Santa Cruz;
MdmX (MDMX-82) and tubulin (T5168) from Sigma; PI3K (#06-496) from
Upstate; actin (ab8229) from Abcam. Nutlin-3a (N6287) and cycloheximide
(C4859) were from Sigma. PI3K and tubulin were used as loading controls.
KU55933 (118502) was from Calbiochem. The CIP (M0290) and phosphatase
treatment protocol were from NEB. Cellular fractionation was performed
according to the manufacturer’s protocol from the NE-PER Nuclear and
Cytoplasmic Extraction Kit (78833) from Thermo Scientific. Protein levels in
Figure 3Cwere quantified by densitometry using the ImageJ software. All other
protein quantification was performed using the Chemidoc XRS+ Molecular
Imaging System from BioRad.
Quantitative Real Time PCR
Total mRNA was isolated according to the Trizol Reagent protocol (Invitrogen)
and cDNA was generated using the SuperScript II First Strand Synthesis Kit
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All data are presented as the ratio of mRNA to Gapdh mRNA.
For the QIAGEN p53 PCR Array experiments, mRNA was isolated using
the RNeasy kit (74104) with DNase (79254) from QIAGEN. cDNA was synthe-
sized using the RT2 First Strand Kit (330401) from QIAGEN. p53 PCR Arrays
(PAMM-027C) were run according to manufacturer’s protocol using the RT2
SYBR Green ROX qPCR Mastermix (330520) from QIAGEN.
Flow Cytometry
For apoptosis, samples were treated according to the Annexin V-FITC
Apoptosis Detection Kit I protocol (BD Pharmingen #556547). Early apoptotic
cells (Annexin Vhigh PIlow) were quantitated and presented. For cell cycle arrest,
treated MEFs were pulsed labeled with 60 mM bromodeoxyuridine (BrdU) for
3 hr. Cells were then trypsinized, fixed in 70% ethanol overnight, incubated
with anti-BrdU antibody (Becton Dickinson #347583) and PI, and analyzed
by flow cytometry. Data are presented as the percentage of cells in S phase
in the treated samples compared to the untreated samples. Flow cytometry
was performed by the UMASS Medical School Flow Cytometry Core Lab.
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